sylvain carras

Has grant

Professeur des Universités - Praticien Hospitalier

Grenoble Alpes University Hospital

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sylvain Carras is a Professeur des Universités - Praticien Hospitalier at the Centre Hospitalier Universitaire Grenoble Alpes, France. His research areas include drug development for lymphomas, targeted therapies, and clinical outcomes related to CAR-T therapies. Recent articles authored by Professor Carras examine various aspects of lymphoma treatment and monitoring, contributing significantly to advancements in oncological care.

Recent Grants

Grant: Open

PHILTER : Polycomb-H1 Interplay during Lymphoma Treatment driving Epigenetic heterogeneity and Resistance.

Open Date: 2024-01-01

Close Date: 2027-12-01

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Jerome Govin

Head of Department

Institute for Advanced Biosciences

FRANCE

View details

Bettina Bisig

Lausanne University Hospital

SWITZERLAND

View details

Blandine GUFFROY

Institut de Cancérologie Strasbourg

FRANCE

View details

Caroline BRET

MCU-PH, head of the Flow Cytometry Laboratory

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

sylvain carras

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Clinical use of circulating tumor DNA analysis in patients with lymphoma

Drug development in MZL: caring for the forgotten child

Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study.

Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study

Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA.

BET inhibition revealed varying MYC dependency mechanisms independent of gene alterations in aggressive B-cell lymphomas.

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.

Collaborators (4)

Jerome Govin

Bettina Bisig

Blandine GUFFROY

Caroline BRET

Make your next move.